Advanced search
Publication Cover
Nanomedicine Volume 7, 2012 - Issue 6
Submit an article Journal homepage
369
Views
3
CrossRef citations to date
0
Altmetric
Review

Emerging Engineered Magnetic Nanoparticulate Probes for Molecular MRI of Atherosclerosis: How Far Have We Come?

Rupinder K Kanwar1 Nanomedicine, Laboratory of Immunology & Molecular Biomedical Research (LIMBR), Center for Biotechnology & Interdisciplinary Biosciences, Institute for Frontier Materials (IFM), Deakin University, Waurn Ponds, Victoria3217, Australia. [email protected]View further author information
,
Rajneesh Chaudhary2 Nanomaterials, Institute for Frontier Materials (IFM), Deakin University, Waurn Ponds, Victoria3217, AustraliaView further author information
,
Takuya Tsuzuki2 Nanomaterials, Institute for Frontier Materials (IFM), Deakin University, Waurn Ponds, Victoria3217, AustraliaView further author information
&
Jagat R Kanwar1 Nanomedicine, Laboratory of Immunology & Molecular Biomedical Research (LIMBR), Center for Biotechnology & Interdisciplinary Biosciences, Institute for Frontier Materials (IFM), Deakin University, Waurn Ponds, Victoria3217, Australia. [email protected]Correspondence[email protected]
View further author information
Pages 899-916 | Published online: 26 Jun 2012

References

  • Kanwar RK , KanwarJR, WangD, OrmrodDJ, KrissansenGW. Temporal expression of heat shock proteins 60 and 70 at lesion-prone sites during atherogenesis in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol.21(12), 1991–1997 (2001).
  • Hansson GK . Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med.352(16), 1685–1695 (2005).
  • Naghavi M , LibbyP, FalkEet al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 108(14), 1664–1672 (2003).
  • Burke AP , FarbA, MalcomGT, LiangYH, SmialekJ, VirmaniR. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N. Engl. J. Med.336(18), 1276–1282 (1997).
  • Murray CJL , LopezAD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet349(9064), 1498–1504 (1997).
  • Libby P , AikawaM. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat. Med.8(11), 1257–1262 (2002).
  • Lamon BD , HajjarDP. Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am. J. Pathol.173(5), 1253–1264 (2008).
  • Glass CK , WitztumJL. Atherosclerosis. The road ahead. Cell104(4), 503–516 (2001).
  • Osborn EA , JafferFA. The year in molecular imaging. JACC Cardiovasc. Imaging3(11), 1181–1195 (2010).
  • Kanwar RK , ChaudharyR, TsuzukiT, KanwarJR. Emerging engineered magnetic nanoparticulate probes for targeted magnetic resonance imaging of atherosclerotic plaque macrophages. Nanomedicine (Lond.)7(5), 735–749(2012).
  • Gimbrone MA , TopperJN, NagelT, AndersonKR, Garcia-CardeñaG. Endothelial dysfunction, hemodynamic forces, and atherogenesisa. Ann. NY Acad. Sci.902(1), 230–240 (2000).
  • Douglas G , ChannonKM. The pathogenesis of atherosclerosis. Medicine38(8), 397–402 (2010).
  • Andrew CN . An overview of the vascular response to injury: a tribute to the late Russell Ross. Toxicol. Lett.112–113(0), 519–529 (2000).
  • Lusis AJ . Atherosclerosis. Nature407(6801), 233–241 (2000).
  • Libby P . Current concepts of the pathogenesis of the acute coronary syndromes. Circulation104(3), 365–372 (2001).
  • Bonetti PO , LermanLO, LermanA. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol.23(2), 168–175 (2003).
  • Diodati JG , DakakN, GilliganDM, QuyyumiAA. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation98(1), 17–24 (1998).
  • Anderson TJ . Assessment and treatment of endothelial dysfunction in humans. J. Am. Coll. Cardiol.34(3), 631–638 (1999).
  • Kanwar JR , KanwarRK, BurrowH, BaratchiS. Recent advances on the roles of NO in cancer and chronic inflammatory disorders. Curr. Med. Chem.16(19), 2373–2394 (2009).
  • De Caterina R , LibbyP, PengHBet al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96(1), 60–68 (1995).
  • Erling F . Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol.47(Suppl. 8), C7–C12 (2006).
  • Tabas I , WilliamsKJ, BorenJ. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation116(16), 1832–1844 (2007).
  • Xu Q . Role of heat shock proteins in atherosclerosis. Arterioscler. Thromb. Vasc. Biol.22(10), 1547–1559 (2002).
  • Morimoto RI , KlineMP, BimstonDN, CottoJJ. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem.32, 17–29 (1997).
  • Kleindienst R , XuQ, WilleitJ, WaldenbergerFR, WeimannS, WickG. Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am. J. Pathol.142(6), 1927–1937 (1993).
  • Bielecka-Dabrowa A , BarylskiM, MikhailidisDP, RyszJ, BanachM. HSP 70 and atherosclerosis – protector or activator? Expert Opin. Ther. Targets13(3), 307–317 (2009).
  • Schett G , XuQ, AmbergerAet al. Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J. Clin. Invest. 96(6), 2569–2577 (1995).
  • Pockley AG , WuR, LemneC, KiesslingR, De Faire U, Frostegard J. Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension36(2), 303–307 (2000).
  • Halcox JP , DeanfieldJ, Shamaei-TousiAet al. Circulating human heat shock protein 60 in the blood of healthy teenagers: a novel determinant of endothelial dysfunction and early vascular injury? Arterioscler. Thromb. Vasc. Biol. 25(11), e141–142 (2005).
  • Herz I , RossoR, RothA, KerenG, GeorgeJ. Serum levels of anti-heat shock protein 70 antibodies in patients with stable and unstable angina pectoris. Acute Card. Care8(1), 46–50 (2006).
  • Hansson GK , LibbyP. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol.6(7), 508–519 (2006).
  • Mandal K , JahangiriM, XuQ. Autoimmunity to heat shock proteins in atherosclerosis. Autoimmun. Rev.3(2), 31–37 (2004).
  • Afek A , GeorgeJ, GilburdBet al. Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J. Autoimmun. 14(2), 115–121 (2000).
  • Rigano R , ProfumoE, ButtariBet al. Heat shock proteins and autoimmunity in patients with carotid atherosclerosis. Ann. NY Acad. Sci. 1107, 1–10 (2007).
  • Langille B , O‘DonnellF. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science231(4736), 405–407 (1986).
  • Joris I , ZandT, MajnoG. Hydrodynamic injury of the endothelium in acute aortic stenosis. Am. J. Pathol.106(3), 394–408 (1982).
  • Walpola PL , GotliebAI, CybulskyMI, LangilleBL. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. Arterioscler. Thromb. Vasc. Biol.15(1), 2–10 (1995).
  • Zand T , HoffmanAH, SavilonisBJet al. Lipid deposition in rat aortas with intraluminal hemispherical plug stenosis: a morphological and biophysical study. Am. J. Pathol. 155(1), 85–92 (1999).
  • Vallance P , ChanN. Endothelial function and nitric oxide: clinical relevance. Heart85(3), 342–350 (2001).
  • Chatzizisis YS , CoskunAU, JonasM, EdelmanER, FeldmanCL, StonePH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J. Am. Coll. Cardiol.49(25), 2379–2393 (2007).
  • Borén J , OlinK, LeeI, ChaitA, WightTN, InnerarityTL. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J. Clin. Invest.101(12), 2658–2664 (1998).
  • Knowles JW , ReddickRL, JennetteJC, SheselyEG, SmithiesO, MaedaN. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-) apoE(-/-) mice are ameliorated by enalapril treatment. J. Clin. Invest.105(4), 451–458 (2000).
  • Hansson GK , HermanssonA. The immune system in atherosclerosis. Nat. Immunol.12(3), 204–212 (2011).
  • Auffray C , FoggD, GarfaMet al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317(5838), 666–670 (2007).
  • Kol A , BourcierT, LichtmanAH, LibbyP. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J. Clin. Invest.103(4), 571–577 (1999).
  • Ellins E , Shamaei-TousiA, SteptoeAet al. The relationship between carotid stiffness and circulating levels of heat shock protein 60 in middle-aged men and women. J. Hypertens. 26(12), 2389–2392 (2008).
  • Zernecke A , ShagdarsurenE, WeberC. Chemokines in atherosclerosis: an update. Arterioscler. Thromb. Vasc. Biol.28(11), 1897–1908 (2008).
  • Boring L , GoslingJ, ClearyM, CharoIF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature394(6696), 894–897 (1998).
  • Gu L , OkadaY, ClintonSKet al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell. 2(2), 275–281 (1998).
  • Watanabe T , FanJ. Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis. Int. J. Cardiol.66(Suppl. 1), S45–S53; discussion S55 (1998).
  • Blankenberg S , BarbauxS, TiretL. Adhesion molecules and atherosclerosis. Atherosclerosis170(2), 191–203 (2003).
  • Zernecke A , LiehnEA, FraemohsLet al. Importance of junctional adhesion molecule-A for neointimal lesion formation and infiltration in atherosclerosis-prone mice. Arterioscler. Thromb. Vasc. Biol. 26(2), e10–e13 (2006).
  • McLaren JE , MichaelDR, AshlinTG, RamjiDP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog. Lipid Res.50(4), 331–347 (2011).
  • Nakashima Y , RainesEW, PlumpAS, BreslowJL, RossR. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler. Thromb. Vasc. Biol.18(5), 842–851 (1998).
  • Kontush A , ChapmanMJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev.58(3), 342–374 (2006).
  • Tabas I . Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol.10(1), 36–46 (2010).
  • Packard RR , LibbyP. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem.54(1), 24–38 (2008).
  • Rudijanto A . The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med. Indones.39(2), 86–93 (2007).
  • Mallat Z , TalebS, Ait-OufellaH, TedguiA. The role of adaptive T cell immunity in atherosclerosis. J. Lipid Res.50(Suppl.), S364–S369 (2009).
  • Moreno PR , Purushothaman K-R, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation113(18), 2245–2252 (2006).
  • De Boer OJ , Van Der Wal AC, Teeling P, Becker AE. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc. Res.41(2), 443–449 (1999).
  • Ehara S , KobayashiY, YoshiyamaMet al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction. Circulation 110(22), 3424–3429 (2004).
  • Tedgui A , MallatZ. Apoptosis as a determinant of atherothrombosis. Thromb. Haemost.86(1), 420–426 (2001).
  • Schaar JA , MullerJE, FalkEet al. Terminology for high-risk and vulnerable coronary artery plaques. Eur. Heart J. 25(12), 1077–1082 (2004).
  • Sukhova GK , SchonbeckU, RabkinEet al. Evidence for increased collagenolysis by interstitial collagenases 1 and -3 in vulnerable human atheromatous plaques. Circulation 99(19), 2503–2509 (1999).
  • Galis ZS , SukhovaGK, LarkMW, LibbyP. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest.94, 2493–2503 (1994).
  • Morishige K , ShimokawaH, MatsumotoYet al. Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo. Cardiovasc. Res. 57(2), 572–585 (2003).
  • Lipinski M j, Fuster V, Fisher Ea, Fayad Za. Technology insight: targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging. Nat. Clin. Pract. Cardiovasc. Med.1, 48–55 (2004).
  • Chen W , CormodeDP, FayadZA, MulderWJM. Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.3(2), 146–161 (2011).
  • Kelly KA , AllportJR, TsourkasA, Shinde-PatilVR, JosephsonL, WeisslederR. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res.96(3), 327–336 (2005).
  • Nahrendorf M , JafferFA, KellyKAet al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114(14), 1504–1511 (2006).
  • Kang HW , TorresD, WaldL, WeisslederR, BogdanovAA. Targeted imaging of human endothelial-specific marker in a model of adoptive cell transfer. Lab. Invest.86(6), 599–609 (2006).
  • Woollard KJ , Chin-DustingJ. Therapeutic targeting of P-selectin in atherosclerosis. Inflamm. Allergy Drug Targets6(1), 69–74 (2007).
  • Jacobin-Valat M-J , Deramchia K, Mornet S et al. MRI of inducible P-selectin expression in human activated platelets involved in the early stages of atherosclerosis. NMR Biomed.24(4), 413–424 (2011).
  • Perez-Balderas F , DavisBG, VankasterenSI. New biodegradable multimeric MPIO contrast agent shows rapid in vitro and in vivo degradation and high sensitivity contrast. Proc. Intl. Soc. Mag. Reson. Med.19, 1689 (2011).
  • McAteer MA , SchneiderJE, AliZAet al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler. Thromb. Vasc. Biol. 28(1), 77–83 (2008).
  • McAteer MA , AkhtarAM, Von Zur Muhlen C, Choudhury RP. An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis209(1), 18–27 (2010).
  • Alsaid H , De Souza G, Bourdillon M-C et al. Biomimetic MRI contrast agent for imaging of inflammation in atherosclerotic plaque of apoE-/- mice: a pilot study. Invest. Radiol.44(3), 151–158. (2009).
  • Smith B , HeverhagenJ, KnoppMet al. Localization to atherosclerotic plaque and biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles (SPIONs) contrast particles for magnetic resonance imaging (MRI). Biomed. Microdevices 9(5), 719–727 (2007).
  • Sosnovik DE , SchellenbergerEA, NahrendorfMet al. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn. Reson. Med. 54(3), 718–724 (2005).
  • Kanwar JR , MahidharaG, KanwarRK. Antiangiogenic therapy using nanotechnological-based delivery system. Drug Discov. Today16(5–6), 188–202 (2011).
  • Kerwin WS , O‘BrienKD, FergusonMS, PolissarN, HatsukamiTS, YuanC. Inflammation in carotid atherosclerotic plaque: a dynamic contrast-enhanced MR imaging study. Radiology241(2), 459–468 (2006).
  • Winter PM , MorawskiAM, CaruthersSDet al. Molecular imaging of angiogenesis in early-stage atherosclerosis with αvβ3-integrin-targeted nanoparticles. Circulation 108(18), 2270–2274 (2003).
  • Winter PM , NeubauerAM, CaruthersSDet al. Endothelial αvβ3 integrin–targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26(9), 2103–2109 (2006).
  • Winter PM , CaruthersSD, ZhangH, WilliamsTA, WicklineSA, LanzaGM. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc. Imaging1(5), 624–634 (2008).
  • Von Zur Muhlen C , Von Elverfeldt D, Moeller JA et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation118(3), 258–267 (2008).
  • Von Zur Muhlen C , PeterK, AliZAet al. Visualization of activated platelets by targeted magnetic resonance imaging utilizing conformation-specific antibodies against glycoprotein IIb/IIIa. J. Vasc. Res. 46(1), 6–14 (2009).
  • Wickline SA , NeubauerAM, WinterPM, CaruthersSD, LanzaGM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J. Magn. Reson. Imaging25(4), 667–680 (2007).
  • Flacke S , FischerS, ScottMJet al. Novel MRI contrast agent for molecular imaging of fibrin. Circulation 104(11), 1280–1285 (2001).
  • Yu X , Song S-K, Chen J et al. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn. Reson. Med.44(6), 867–872 (2000).
  • Pan D , SenpanA, CaruthersSDet al. Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids. Chem. Commun. (22), 3234–3236 (2009).
  • Pan D , CaruthersSD, HuGet al. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J. Am. Chem. Soc. 130(29), 9186–9187 (2008).
  • Senpan A , CaruthersSD, RheeIet al. Conquering the dark side: colloidal iron oxide nanoparticles. ACS Nano 3(12), 3917–3926 (2009).
  • McCarthy JR , PatelP, BotnaruI, HaghayeghiP, WeisslederR, JafferFA. Multimodal nanoagents for the detection of intravascular thrombi. Bioconj. Chem.20(6), 1251–1255 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.